Lineage-specific chimaerism after stem cell transplantation in children following reduced intensity conditioning: Potential predictive value of NK cell chimaerism for late graft rejection

Leukemia

Volumn 17, Issue 10, 2003, Pages 1934-1942

  Matthes Martin, S ^a   Lion, T ^b   Haas, O A ^b   Frommlet, F ^c   Daxberger, H ^b   Konig M ^b   Printz, D ^b   Scharner, D ^b   Eichstill, C ^b   Peters, C ^a   Lawitschka, A ^a   Gadner, H ^a,b   Fritsch, G ^b  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Allogeneic stem cell transplantation; Cell subsets; Children; Chimaerism; NK cell; Rejection

Indexed keywords

BUSULFAN; CD14 ANTIGEN; CD15 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THIOTEPA; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER PATIENT; CELL LINEAGE; CELL NUCLEUS; CELL SELECTION; CELL SUBPOPULATION; CHILD; CHILDHOOD LEUKEMIA; CHIMERA; CHRONIC GRANULOMATOUS DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DONOR; FANCONI ANEMIA; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; GRAFT REJECTION; GRANULOCYTE; HEMOPHAGOCYTIC SYNDROME; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HYPERIMMUNOGLOBULINEMIA M; INFANT; KIDNEY CARCINOMA; LEUKOCYTE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MONOCYTE; MYELODYSPLASIA; NATURAL KILLER CELL; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TANDEM REPEAT; THALASSEMIA; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS; WHOLE BODY RADIATION; WISKOTT ALDRICH SYNDROME; CLASSIFICATION; FAMILY; FEMALE; HISTOCOMPATIBILITY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MALE; METHODOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SIBLING;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FAMILY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KILLER CELLS, NATURAL; MALE; RETROSPECTIVE STUDIES; SIBLINGS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TISSUE DONORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING;

EID: 0142182271     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403087     Document Type: Article

References (70)

1. Gluckman E, Bussel A, Benbunan M, Broquet M, Schaison G, Dausset J et al. Treatment of bone marrow aplasia by allogenic bone marrow grafts. Nouv Presse Med 1975; 19: 1177-1182.
2. Hansen G, Dupont B, Faber V, Jakobson B, Juhl F, Nielsen L et al. Lymphocyte chimerism after bone marrow transplantation. Surface markers and in vitro function of donor and recipient lymphocyte subpopulations. Scand J Immunol 1977; 6: 299-303.
3. Starling K, Faletta J, Fernbach D. Immunologic chimerism as evidence of bone marrow graft acceptance in an identical twin with acute lymphocytic leukemia. Exp Hematol 1975; 3: 244-248.
4. Hancock JP, Goulden NJ, Oakhill A, Steward CG. Quantitative analysis of chimerism after allogeneic bone marrow transplantation using immunomagnetic selection and fluorescent microsatellite PCR. Leukemia 2003; 17: 247-251.
5. Lapointe C, Forest L, Lussier P, Busque L, Lagace F, Perrault C et al. Sequential analysis of early hematopoietic reconstitution following allogeneic bone marrow transplantation with fluorescence in situ hybridization (FISH). Bone Marrow Transplant 1996; 17: 1143-1148.
6. Lion T. Summary: reports on quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection. Leukemia 2003; 17: 252-254.
7. Scharf S, Smith A, Hansen J, McFarland C, Erlich H. Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood 1995; 85: 1954-1963.
8. Bader P, Beck J, Frey A, Schlegel P, Hebarth H, Handgretinger R et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant 1998; 21: 487-495.
9. Casado L, Steegmann J, Pico M, Requena M, Ramirez M, Madero L et al. Study of chimerism in long-term survivors after bone marrow transplantation for severe acquired aplastic anemia. Bone Marrow Transplant 1996; 18: 405-409.
10. Frankel W, Chan A, Corringham R, Shepherd S, Rearden A, Wang-Rodriguez J. Detection of chimerism and early engraftment after allogeneic peripheral stem cell or bone marrow transplantation by short tandem repeats. Am J Hematol 1996; 52: 281-287.
11. Amrolia P, Vulliamy T, Vassiliou G, Lawson SE, Bryon J, Kaeda J et al. Analysis of chimerism in thalassaemic children undergoing stem cell transplantation. Br J Haematol 2001; 114: 219-225.
12. Andreani M, Nesci S, Lucarelli C, Tonucci P, Angelucci E, Persini B et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant 2000; 25: 401-404.
13. Gomez J, Garcia M, Serrano J, Sanchez J, Falcon M, Castillejo J et al. Chimerism analysis in longterm survivors patients after bone marrow transplantation for severe aplastic anemia. Haematologica 1997; 82: 588-591.
14. Hill RS, Petersen FB, Storb R, Appelbaum FR, Doney K, Dahlberg S et al. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood 1986; 67: 811-816.
15. Mital M, Curtis A, Spencer V, Barge D, Skinner R. Delayed engraftment and mixed chimerism after HLA-identical sibling donor BMT in Fanconi anaemia. Bone Marrow Transplant 1999; 24: 201-204.
16. McSweeney P, Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant 2001; 5: 192-203.
17. Shimoni A, Nagler A. Non-myeloablative stem cell transplantation (NST): chimerism testing as a guidance for immune-therapeutic manipulations. Leukemia 2001; 15: 1967-1975.
18. Carella AM, Champlin R, Slavin S, McSweeney PA, Storb R. Mini-allografts: ongoing trials in humans. Biol Blood Marrow Transplant. 2000; 25: 345-350.
19. Horwitz ME, Barrett AJ, Brown MR, Carter CS, Childs R, Gallin JI et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 2001; 344: 881-888.
20. Amrolia P, Gaspar HB, Hassan A, Webb D, Jones A, Sturt N et al. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 2000; 96: 1239-1246.
21. Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234-3241.
22. Dubovsky J, Daxberger H, Fritsch G, Printz D, Peters C, Matthes S et al. Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection. Leukemia 1999; 13: 2060-2069.
23. Mackinnon S, Barret L, Heller G, O'Reilly R. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood 2001; 83: 3409-3416.
24. Mattsson J, Uzunel M, Remberger M, Ringden O. T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 2001; 71: 433-439.
25. Maury S, Jouault H, Kuentz M, Vernant JP, Tulliez M, Cordonnier C et al. Chimerism analysis by lineage-specific fluorescent polymerase chain reaction in secondary graft failure after allogeneic stem cell transplantation. Transplantation 2001; 71: 374-380.
26. Niiya H, Kanda Y, Saito T, Ohnishi T, Kanai S, Kawano Y et al. Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan. Haematologica 2001; 86: 1071-1074.
27. Winiarski J, Mattson J, Gustafsson A, Wester D, Borgstrom B, Ringden O et al. Engraftment and chimerism, particularly of T- and B-cells, in children undergoing allogeneic bone marrow transplantation. Pediatr Transplant 1998; 2: 150-156.
28. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate-mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-1629.
29. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
30. Fritsch G, Printz D, Stimpfl M, Dworzak M, Witt V, Potschger U et al. Quantification of CD34+ cells: comparison of methods. Transfusion 1997; 37: 775-784.
31. Schraml E, Daxberger H, Watzinger F, Lion T. Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Vienna experience. Leukemia 2003; 17: 224-227.
32. Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2001; 7: 473-485.
33. van Leeuwen JF, van Tol MJ, Bodzinga BG, Wijnen JT, van der KM, Joosten AM et al. Detection of mixed chimerism in flow-sorted cell subpopulations by PCR-amplified VNTR markers after allogeneic bone marrow transplantation. Br J Haematol 1991; 79: 218-225.
34. Bader P, Holle W, Klingebiel T, Handgretinger R, Benda N, Schlegel P et al. Mixed hematopoietic chimerism after alogeneic marrow transplantation: the impact of quantitative PCR analysis for prediction of relapse and graft rejection in children. Bone Marrow Transplant 2001; 19: 697-702.
35. Schattenberg A, De Witte T, Salden M, Vet J, Van Dijk B, Smeets D et al. Mixed hematopoietic chimerism after allogeneic transplantation with lymphocyte-depleted bone marrow is not associated with a higher incidence of relapse. Blood 1989; 73: 1367-1372.
36. Lion T, Daxberger H, Dubovsky J, Filipcik P, Fritsch G, Printz D et al. Analysis of chimerism within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation. Leukemia 2001; 15: 307-310.
37. Mattsson J, Uzunel M, Tammik L, Aschan J, Ringden O. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 2001; 15: 1976-1985.
38. Thiede C, Bornhauser M, Oelschlagel U, Brendel C, Leo R, Daxberger H et al. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification short tandem repeat-markers. Leukemia 2001; 15: 293-302.
39. Zetterquist H, Mattson J, Uzunel M, Nasman-Bjork I, Svenberg P, Bayat G et al. Mixed chimerism in the b cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia. Bone Marrow Transplant 2001; 25: 843-851.
40. Battaglia M, Anreani M, Manna M, Nesci S, Tonucci P, Persini B et al. Coexistence of two functioning T-cell repertoires in healthy ex-Thalassemics bearing a persistent mixed chimerism years after bone marrow transplantation. Blood 1999; 94: 3432-3438.
41. Haddad E, Le Deist F, Aucouturier P, Cavazzana-Calvo M, Blanche S, De Saint Basile G et al. Long-term chimerism and b-cell function after bone marrow transplantation in patients with severe combined immunodeficiency with B-cells: a single-center study of 22 patients. Blood 1999; 94: 2923-2930.
42. Passweg JR, Meyer-Monard S, Gregor M, Favre C, Heim D, Ebnoether M et al. High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation. Bone Marrow Transplant 2002; 30: 267-271.
43. Perez-Simon JA, Caballero D, Diez-Campelo M, Lopez-Perez R, Mateos G, Canizo C et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002; 16: 1423-1431.
44. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molidrem J, Chauncey TR et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
45. Roux E, Helg C, Dumont-Girard F, Chapuis B, Jeannet M, Roosnek E. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 1996; 87: 3984-3992.
46. Sykes M, Preffer F, McAfee S, Saidman S, Weymouth D, Andrews D et al. Mixed lymphohematopoietic chimerism and graft versus lymphoma effects after nonmyeloablative therapy and HLA-mismatched bone marrow transplantation. Lancet 1999; 16: 1755-1759.
47. Schaap N, Schattenberg A, Mensink E, Preijers F, Hillegers M, Knops R et al. Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation. Leukemia 2002; 16: 13-21.
48. Gyger M, Baron C, Forest L, Lussier P, Lagace F, Bissonnette I et al. Quantitative assessment of hematopoietic chimerism after allogeneic bone marrow transplantation has predictive value for the occurrence of irreversible graft failure and graft-vs-host disease. Exp Hematol 1998; 26: 426-434.
49. Mackinnon S, Barnett L, Bourhis JH, Black P, Heller G, O'Reilly RJ. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood 1992; 80: 3235-3241.
50. Valcarcel D, Martino R, Caballero D, Mateos M, Perez-Simon J, Canals C et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning. Bone Marrow Transplant 2003; 31: 387-392.
51. Kreiter S, Winkelmann N, Schneider PM, Schuler M, Fischer T, Ullmann AJ et al. Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 2001; 28: 157-161.
52. Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la RJ, Brunet S et al. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood 2001; 97: 383-387.
53. Görner M, Kordelas L, Thalheimer M, Luft T, Pfeiffer S, Ustaoglu F et al. Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine. Bone Marrow Transplant 2002; 29: 621-624.
54. Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100: 3108-3114.
55. Bornhauser M, Thiede C, Platzbecker U, Jenke A, Helwig A, Plettig R et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 2001; 7: 2254-2262.
56. Bertrand Y, Landais P, Friedrich W, Gerritson E, Morgan G, Fasth A et al. Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell depleted bone marrow transplantation: a retrospective European survey from the European group for bone marrow transplantation and the European society for immunodeficiency. J Pediatr 1999; 134: 740-748.
57. Kawai T, Wee SL, Bazin H, Latinne D, Phelan J, Boskovic S et al. Association of natural killer cell depletion with induction of mixed chimerism and allograft tolerance in non-human primates. Transplantation 2000; 70: 368-374.
58. Lee LA, Sergio JJ, Sykes M. Natural killer cells weakly resist engraftment of allogeneic, long-term, multilineage-repopulating hematopoietic stem cells. Transplantation 1996; 61: 125-132.
59. Neipp M, Gammie JS, Exner BG, Li S, Chambers WH, Pham SM et al. A partial conditioning approach to achieve mixed chimerism in the rat: depletion of host natural killer cells significantly reduces the amount of total body irradiation required for engraftment. Transplantation 1999; 68: 369-378.
60. Tiberghien P, Longo DL, Wine JW, Alvord WG, Reynolds CW. Anti-asialo GM1 antiserum treatment of lethally irradiated recipients before bone marrow transplantation: evidence that recipient natural killer depletion enhances survival, engraftment, and hematopoietic recovery. Blood 1990; 76: 1419-1430.
61. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
62. Bornhauser M, Thiede C, Brendel C, Geissler G, Oelschlagel U, Neubauer A et al. Stable engraftment after megadose blood stem cell transplantation across the HLA barrier: the case for natural killer cells as graft-facilitating cells. Transplantation 1999; 68: 87-88.
63. Murphy WJ, Koh CY, Raziuddin A, Bennett M, Longo DL. Immunobiology of natural killer cells and bone marrow transplantation: merging of basic and preclinical studies. Immunol Rev 2001; 181: 279-289.
64. Shilling H, McQueen K, Cheng N, Shizuru J, Negrin R, Parham P. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 2003; 101: 3730-3740.
65. Farag S, Fehniger T, Ruggeri L, Velardi A, Caliguri M. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935-1947.
66. Gagne K, Brizard G, Gueglio B, Milpied N, Herry P, Bonneville F et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 2002; 63: 271-280.
67. D'Orazio J, Burke J, Stein-Streilein J. Staphylococcal Enterotoxin B activates purified NK cells to secrete IFN-y but requires T lymphocytes to augment NK cytotoxicity. J Immunol 1994; 154: 1014-1023.
68. Groh V, Rhinehart R, Randolph-Habecker J, Topp M, Riddell S, Spies T. Costimulation of CDaβ T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001; 2: 255-260.
69. Johnson T, Hong S, Van Kaer L, Koezuka Y, Graham B. NK T cells contribute to expansion of CD8+ T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol 2002; 76: 4294-4303.
70. Das S, Varalakshmi C, Kumari A, Patel M, Khar A. Target cell induced activation of NK cells in vitro: cytokine production and enhancement of cytotoxic function. Cancer Immunol Immunother 2001; 50: 428-436.